- Home
- ANSC vs ERAS Comparison
ANSC vs ERAS Comparison
Compare ANSC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- ERAS
- Stock Information
- Founded
- ANSC 2021
- ERAS 2018
- Country
- ANSC United States
- ERAS United States
- Employees
- ANSC N/A
- ERAS N/A
- Industry
- ANSC
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- ERAS Health Care
- Exchange
- ANSC Nasdaq
- ERAS Nasdaq
- Market Cap
- ANSC 466.6M
- ERAS 439.7M
- IPO Year
- ANSC 2023
- ERAS 2021
- Fundamental
- Price
- ANSC $11.05
- ERAS $2.31
- Analyst Decision
- ANSC
- ERAS Buy
- Analyst Count
- ANSC 0
- ERAS 6
- Target Price
- ANSC N/A
- ERAS $3.67
- AVG Volume (30 Days)
- ANSC 385.1K
- ERAS 1.4M
- Earning Date
- ANSC 01-01-0001
- ERAS 11-07-2025
- Dividend Yield
- ANSC N/A
- ERAS N/A
- EPS Growth
- ANSC N/A
- ERAS N/A
- EPS
- ANSC 0.14
- ERAS N/A
- Revenue
- ANSC N/A
- ERAS N/A
- Revenue This Year
- ANSC N/A
- ERAS N/A
- Revenue Next Year
- ANSC N/A
- ERAS N/A
- P/E Ratio
- ANSC $81.39
- ERAS N/A
- Revenue Growth
- ANSC N/A
- ERAS N/A
- 52 Week Low
- ANSC $10.38
- ERAS $1.01
- 52 Week High
- ANSC $11.12
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ANSC 54.21
- ERAS 51.18
- Support Level
- ANSC $11.07
- ERAS $2.34
- Resistance Level
- ANSC $11.01
- ERAS $2.54
- Average True Range (ATR)
- ANSC 0.03
- ERAS 0.16
- MACD
- ANSC -0.01
- ERAS -0.03
- Stochastic Oscillator
- ANSC 41.67
- ERAS 28.42
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.